Arrhythmogenic cardiomyopathy (ACM) is a rare, inherited cardiac disorder associated with ventricular arrhythmias, fibrofatty myocardial replacement, and sudden cardiac death (SCD). Mutations in the plakophilin-2 (PKP2) gene are the most common cause of ACM. Currently, there are no diseasemodifying therapies for PKP2-ACM; standard care focuses on arrhythmia control and SCD prevention through antiarrhythmics, ICDs, and ablation, without addressing the underlying cause.
Innovation Partner Roundtable – Targeting the Root, Not Just the Rhythm: Next-Generation Strategies for PKP2-ACM – Powered by Lexeo
September 05, 2025 | 09:45 AM (EDT) - 10:30 AM (EDT)